Protein engineering has long been hostage to a humble bottleneck: bacteria. Even when computational tools propose hundreds of promising candidate sequences, each one must traditionally be cloned into a plasmid, transformed into microbes, grown overnight, purified, sequence-verified, and only then transferred into mammalian cells for testing. That pipeline consumes weeks of labor and thousands of dollars before a single data point emerges. Now a team led by Michael Lin at Stanford University reports a platform that deletes the microbial middleman entirely, assembling complete genes by PCR and transfecting them straight into mammalian cells, with the entire journey from primer receipt to cell-based screening compressed into less than a single workday. The method, described in Molecular Systems Biology, is called Microbe-Independent Deep Assembly and Screening, or MIDAS, and its developers argue it can transform both the speed and the scope of protein optimization.
The core logic of MIDAS is disarmingly simple. Instead of building plasmids, researchers design overlapping PCR fragments that together encode a complete transcription unit, including a promoter, the variant coding sequence, and a polyadenylation signal. Mutations are introduced through primers at defined target regions, and a secondary overlap-extension PCR stitches the fragments into full-length genes. Each PCR product encodes one defined variant and is transfected into one well of a multiwell plate, so the association between sequence and measured function is preserved by well position alone. Because no ligation, transformation, bacterial culture, plasmid purification, or sequence verification is required, generating 384 variants takes roughly four hours of hands-on time and about 2,000 dollars in reagents, compared with an estimated 192 hours and 20,000 dollars for conventional cloning of the same number of constructs.
The platform comes in several flavors that expand its reach beyond single-site substitutions. Polytemplated monofocal MIDAS, or MIDAS-PM, uses multiple plasmid templates to generate arrays of mutants at one location. Polytemplated polyfocal MIDAS, or MIDAS-PP, extends this to combinations of changes at multiple sites by mixing primary PCR products combinatorially. Most notably, the team developed monotemplated protocols, MIDAS-MM and MIDAS-MP, which work from a single plasmid template. The trick lies in adding unique DNA tags to the 5-prime ends of the outermost primers, so that secondary PCR primers recognize only the assembled primary products and never re-amplify the parental plasmid. Sequencing confirmed that this nested-primer design eliminates template contamination, meaning researchers can begin mutagenizing a protein of interest immediately without first subcloning it into multiple backbone plasmids.
To demonstrate the method, the team took on an ambitious target: a bioluminescent indicator for acetylcholine, a neurotransmitter central to arousal, attention, learning, and memory, and one whose signaling declines early in Alzheimer’s, Parkinson’s, and Lewy body dementias. Fluorescent acetylcholine sensors exist, but they require implanted optical elements to deliver excitation light, which is impractical for moving organs outside the brain. A bioluminescent sensor, by contrast, generates its own light and could report cholinergic activity noninvasively anywhere in the body. The researchers built their prototype, ACh-NeuBI0.1, by inserting split NanoLuc luciferase fragments into OpuBC, a bacterial periplasmic binding protein previously engineered to bind acetylcholine over choline. The initial construct responded to acetylcholine with a modest 22 percent luminescence increase, a starting point that would demand extensive optimization.
MIDAS delivered that optimization in rapid iterative rounds. First, MIDAS-MP screened all 36 combinations of glycine linker lengths connecting the binding protein to the luciferase fragments, identifying a configuration that boosted responsiveness by roughly 50 percent. Next, MIDAS-MM tested all 20 amino acids at a single linker position, revealing that phenylalanine improved the response to about 80 percent. A third round tuned the energetics of luciferase fragment assembly by screening SmBiT variants, finding that a three-residue C-terminal truncation raised the response to approximately 2.5-fold. The team then fused the orange fluorescent protein mScarlet-I to the sensor, enabling resonance energy transfer that shifts a portion of the emission above 610 nanometers, wavelengths that penetrate tissue far more effectively than NanoLuc’s native blue light. At each step, plasmid-based validation confirmed that the PCR-transfected results were reliable.
The deepest round of engineering showcased MIDAS’s capacity for true combinatorial saturation mutagenesis. Guided by computational structure predictions from Chai-1, the researchers selected 16 sites around the acetylcholine-binding pocket and screened every possible amino acid at each, uncovering beneficial mutations at three second-shell positions. Because positions 560 and 610 sit close together in space, the team then used MIDAS-MP to test all 400 combinations of side chains at those two residues. Two winners emerged: variant QAE, named ACh-NeuBI1b, which achieved the highest affinity at 188 micromolar, and variant QED, named ACh-NeuBI1c, which suppressed baseline luminescence to deliver maximum contrast. Strikingly, ACh-NeuBI1c responded to 100 micromolar acetylcholine with a 640 percent signal increase, a 29-fold improvement over the original prototype.
The mathematics of why this matters are sobering. Seven of the nine beneficial amino acid changes discovered in the study required two or three nucleotide substitutions. Under error-prone PCR, a functional clone carrying two specific mutations appears roughly once in every 71 million clones, and some combinations once in 140 million, numbers far beyond what multiwell screening can reach. Deterministic PCR assembly sidesteps this barrier by constructing exactly the variants of interest, one per well, whether that means 20 samples for one site or 400 for two. The approach also outperforms degenerate oligonucleotide libraries, which require oversampling that balloons combinatorially: two sites of saturation mutagenesis would demand more than 10,000 screened samples, roughly 25 times what MIDAS requires.
The team applied the same logic to NanoLuc luciferase itself, performing saturation mutagenesis at all 25 residues lining or influencing the substrate-binding pocket, generating 500 variants in a single MIDAS-MM campaign. A D108N mutation improved photon production across three different substrates, while D108S, which requires two adjacent nucleotide changes and would be vanishingly rare in random libraries, selectively enhanced activity on the aqueous substrate FFz. Beyond engineering, the complete activity matrix enabled sequence-fitness analysis, mapping which active-site positions tolerate substitution and which are intolerable, and revealing substrate-specificity determinants whose locations often defied structural prediction. Because NanoLuc produces too few photons for fluorescence-activated cell sorting, the multiwell format proved essential, connecting MIDAS to the gold-standard analytical assays, from luminescence to absorbance to chromatography, that apply to most enzymes.
The biological payoff extended from cell culture into living animals. In primary cortical neurons, ACh-NeuBI1b and ACh-NeuBI1c achieved acetylcholine responses of up to 200-fold while maintaining selectivity over choline and other neurotransmitters. When expressed in mouse liver by hydrodynamic transfection, the optimized indicators detected intraperitoneally administered acetylcholine with signal increases of up to 173-fold, far exceeding the 30-fold response of the pre-optimization sensor, while an unregulated control reporter showed no response. The developers emphasize that improvements measured in mammalian cells, including affinity gains that did not reproduce when proteins were screened as bacterial periplasmic constructs, translated directly into in vivo performance, underscoring the value of screening in the environment where a protein must actually work.
Looking forward, the authors position MIDAS as a data engine for the machine-learning era of protein design. Computational models excel at proposing candidate sequences but cannot reliably identify the single best one, and they remain poorly trained on the dynamic conformational changes underlying enzyme catalysis and biosensor activation. By generating hundreds of precisely defined variants with high-quality functional measurements in mammalian cells within a day, MIDAS can supply exactly the kind of dense sequence-fitness datasets that such models need. The method blurs the traditional boundary between screening and analysis, unifying them in a single workflow that is roughly 48 times faster and ten times cheaper than cloning-based approaches. For laboratories optimizing biosensors, enzymes, or therapeutic proteins in mammalian systems, the bacterial incubator may no longer be the obligatory first stop.
Subject of Research: A cloning-free PCR-based platform for rapid protein engineering and sequence-fitness analysis in mammalian cells
Article Title: Fast analysis and engineering of protein function by microbe-independent deep assembly and screening
Article References: Wu, Y., Wang, P., Liu, L. X., Song, D., Qin, Q., Gao, C., Hageman, M., Kirkland, T. A., Su, Y., & Lin, M. Z. (2026). Fast analysis and engineering of protein function by microbe-independent deep assembly and screening. Molecular Systems Biology, 22(6), 1003-1034. https://doi.org/10.1038/s44320-026-00210-z
Image Credits: AI Generated
DOI: 10.1038/s44320-026-00210-z
Keywords: protein engineering, MIDAS, PCR assembly, mammalian cells, directed evolution, bioluminescent indicator, acetylcholine, NanoLuc, saturation mutagenesis, sequence-fitness analysis, biosensors, Molecular Systems Biology
Cite Scienmag News
APA MLA Chicago
Joseph Henderson. (October 1, 2026). PCR-Only Protein Engineering Platform Skips Bacteria and Builds Better Biosensors in a Day. Scienmag. https://scienmag.com/pcr-only-protein-engineering-platform-skips-bacteria-and-builds-better-biosensors-in-a-day/
Joseph Henderson. “PCR-Only Protein Engineering Platform Skips Bacteria and Builds Better Biosensors in a Day.” Scienmag, 1 October 2026, https://scienmag.com/pcr-only-protein-engineering-platform-skips-bacteria-and-builds-better-biosensors-in-a-day/. Accessed 1 October 2026.
Joseph Henderson. “PCR-Only Protein Engineering Platform Skips Bacteria and Builds Better Biosensors in a Day.” Scienmag. October 1, 2026. https://scienmag.com/pcr-only-protein-engineering-platform-skips-bacteria-and-builds-better-biosensors-in-a-day/
Copy citation Download RIS
Tags: accelerating biosensor designacetylcholinebioluminescent indicatorbiosensorsbypassing bacterial cloning in protein engineeringcomputational protein design without microbesdirect mammalian cell transfectiondirected evolutionhigh-throughput gene assemblyinnovative molecular biology techniquesmammalian cellsmicrobial-free gene assemblyMIDASMIDAS protein engineering methodMolecular Systems BiologyNanoLucPCR assemblyPCR-based biosensor developmentProtein Engineeringrapid protein optimization platformsaturation mutagenesissequence-fitness analysisstreamlined protein screening process
